Safety of shortened infusion times for combined ipilimumab and nivolumab

Gassenmaier, Maximilian; Lipp, Hans-Peter; Scheu, Alexander; Wagner, Nikolaus Benjamin; Kofler, Lukas; Mueller, Alisa; Doecker, Dennis; Eigentler, Thomas Kurt; Garbe, Claus; Forschner, Andrea

dc.contributor.author	Gassenmaier, Maximilian
dc.contributor.author	Lipp, Hans-Peter
dc.contributor.author	Scheu, Alexander
dc.contributor.author	Kofler, Lukas
dc.contributor.author	Eigentler, Thomas
dc.contributor.author	Garbe, Claus
dc.contributor.author	Wagner, Nikolaus B.
dc.contributor.author	Müller, Alisa
dc.contributor.author	Döcker, Dennis Miklas
dc.contributor.author	Forschner, Andrea Lydia
dc.date.accessioned	2020-01-20T14:19:58Z
dc.date.available	2020-01-20T14:19:58Z
dc.date.issued	2018
dc.identifier.issn	1432-0851
dc.identifier.uri	http://hdl.handle.net/10900/97201
dc.language.iso	en	en
dc.publisher	Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00262-017-2075-y	de_DE
dc.subject.ddc	610	de_DE
dc.subject.ddc	570	de_DE
dc.title	Safety of shortened infusion times for combined ipilimumab and nivolumab	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_04613
utue.publikation.seiten	135-140	de_DE
utue.personen.roh	Gassenmaier, Maximilian
utue.personen.roh	Lipp, Hans-Peter
utue.personen.roh	Scheu, Alexander
utue.personen.roh	Wagner, Nikolaus Benjamin
utue.personen.roh	Kofler, Lukas
utue.personen.roh	Mueller, Alisa
utue.personen.roh	Doecker, Dennis
utue.personen.roh	Eigentler, Thomas Kurt
utue.personen.roh	Garbe, Claus
utue.personen.roh	Forschner, Andrea
dcterms.isPartOf.ZSTitelID	Cancer Immunology Immunotherapy	de_DE
dcterms.isPartOf.ZS-Issue	1	de_DE
dcterms.isPartOf.ZS-Volume	67	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE